

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 12-16 are pending in the application, with claim 12 being the sole independent claim. Claims 1-5, 7, 8, 10 and 11 are sought to be cancelled without prejudice to or disclaimer of the subject matter therein. New claims 12-16 are sought to be added. These changes are believed to introduce no new matter, and their entry is respectfully requested.

New claim 12 is directed to compositions comprising anthranilic acid amides of the formula II-1 and compound designated I-a-4, buprofezin, flonicamid, or pirimicarb as mixing partners. Support for the definition of the anthranilic acid amide may be found on page 8 of the specification; and support for the mixing partners may be found on page 21 of the specification.

Based on the above amendment and the following remarks, Applicants respectfully request that the Examiner reconsider all outstanding objections and rejections and that they be withdrawn.

Rejection under 35 U.S.C. § 102(a)

The rejection of claims 1-5, 7, 8 and 10 under 35 U.S.C. § 102(a) as being anticipated by International Patent Application No. WO 03/015518 A1 (hereinafter "Lahm") is respectfully traversed.

The Examiner is of the opinion that Lahm teaches the claimed composition. Applicants respectfully disagree.

Lahm teaches a group of potentially millions of combinations without any rationale for selecting components of the claimed composition. Applicants respectfully submit that there is no rationale for choosing the claimed composition from the numerous possibilities of Lahm. Lahm recites compositions with anthranilic acid amides and various mixing partners including, among the vast multitude of options, some compounds recited in the present claims. However, there is no explicit disclosure of a composition comprising a compound of formula I-a-4, buprofezin, flonicamid or pirimicarb, together with a compound of formula II-1. Moreover, Lahm recites long lists of potential mixing partners without any specific teaching of synergistic effects and without citing any mixing ratios for these compositions.

In contrast, in the present application optimum mixing ratios are described and a synergistically enhanced efficacy is demonstrated for a composition of formula I-a-4, buprofezin, or flonicamid together with a compound of formula II-1 as typical examples (see pages 42-51). These combinations and synergistic results are not described by Lahm.

Accordingly, Applicants respectfully request that the rejection of claims 1-5, 7, 8 and 10 under 35 U.S.C. § 102(a) as being anticipated by Lahm be withdrawn.


Conclusion

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert W. Esmond
Attorney for Applicants
Registration No. 32,893

Date: March 31, 2009

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

956494_1.DOC